Non-Small Cell Lung Cancer

Pneuma is working with a leading cancer research center in the US to develop inhaled recombinant protein therapies for non-small cell lung cancer. Pneuma’s recombinant proteins, alone or in combination with systemic delivery, could improve outcomes for patients with non-small cell lung cancer.

As part of our oncology program, we have licensed a portfolio of checkpoint inhibitors (i.e., monoclonal antibodies) from Leads Biolabs, Inc. to potentially treat non-small cell lung cancer and precancerous conditions. We currently have a joint development program with a leading cancer center to develop inhaled therapies with our licensed checkpoint inhibitors, alone or in combination with systemic delivery. Our therapeutic platform is uniquely designed for the delivery of large molecules such as checkpoint inhibitors.